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Purpose: Long-term clinical usage of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with 
significant side effects - gastrointestinal lesions, bleeding and nephrotoxicity. Therefore, the discovery of 
new safer antiinflammatory drugs represents a challenging goal for this research area. 
Methods: Various derivatives of 3-(2-aminopyrimidin-4-yl) indoles viz. 4-(4-substitutedphenyl)-6-(2-(4-
substitutedphenyl)-1H-indol-3-yl) pyrimidin-2-amine (4a-4r) were synthesized by cyclization of (3-(4-
substitutedphenyl)-1-(2-(4-substitutedphenyl)-1H-indol-3-yl) prop-2-en-1-one) of indole with guanidine 
hydrochloride in the presence of sodium isopropoxide. Their structures were confirmed by FTIR, 
1
H 
NMR and elemental analysis. These compounds were investigated for their analgesic, inflammatory and 
ulcerogenic activities. 
Results:  All the compounds tested (4a-4r) showed analgesic and inflammatory activities. Seven 
compounds (4d, e, h, j, k, q, p) out of 18 compounds showed antiinflammatory activity comparable to 
that of the reference standard, indomethacin, but with much lower ulcerogenic action. Compounds 4j 
and 4k showed 87.4 and 88.2 % inhibition of paw edema, 78.5 and 76.6 % protection against acetic 
acid-induced writhings and 0.89 and 1.12 of severity index, respectively, compared to 92.7 %, 82.8 % 
and 2.2, respectively, for indomethacin.  
Conclusion: The results show that incorporation of an appropriately substituted pyrimidine ring in indole 
nucleus can afford molecules with good analgesic and anti-inflammatory activities but with reduced 
gastric irritation. 
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INTRODUCTION 
 
Non-steroidal anti-inflammatory agents 
(NSAIDS) continue to be one of the most 
widely used groups of therapeutic agents. 
They are used for the treatment of 
inflammation including pain, pyrexia and 
rheumatoid arthritis. With increasing life 
expectancy, it is not surprising that the 
development of newer NSAIDs continues at a 
rapid pace. Almost all the NSAIDs currently in 
clinical use are highly acidic in nature and 
suffer from the drawback of gastrointestinal 
toxicity [1]. 
 
Indole alkaloids have proved to be 
medicinally important natural compounds. 
Indole ring constitutes an important template 
for drug design such as the classical NSAIDs 
indomethacin and indoxole. Furthermore, 
indole derivatives have been reported to 
possess promising biological activities 
including analgesic, anti-inflammatory [2-5], 
antihypertensive [6], anticonvulsant [7], 
antimicrobial [8-9] and selective 
cyclooxygenase 2 COX 2 inhibitory activities 
[10-12]. Thus, efficient synthesis of novel 
substituted indole derivative compounds still 
represent highly pursued objective. The 
substitution of heterocyclic moiety at the 3- 
position of indole ring markedly influences 
anti-inflammatory activity [13]. 
 
Design and synthesis of novel NSAIDs 
continues to be explored in order to achieve 
agents with better efficacy and safety profile. 
The diarylheterocycle class of compounds 
has been investigated extensively as COX 2 
inhibitors. In contrast, relatively few reports 
document structural modifications of the 
existing NSAIDs into better drugs [14]. Thus, 
a major objective of this study was to explore 
the indole nucleus of indomethacin, an 
NSAID, for structural modification in order to 
produce potential antiinflammatory agents. 
Furthermore, since pyrimidine derivatives 
have also been reported to possess potent 
anti-inflammatory activity [15-17], a second 
objective of this work, therefore, was to 
synthesize some indole derivatives 
possessing a pyrimidine moiety at 3- position 
of 2-phenyl indoles to obtain compounds (4a-






All the reagents and solvents used in the 
synthesis work were of laboratory grade and 
procured from either SD Fine Chemicals, 
Qualigens or Sigma, India. All the solvents 
were dried and distilled before use. The 
animals used were procured from our 
institute’s animal house.  
 
Synthesis of 2-(4-substitutedphenyl) 
indole (1a-1c) 
 
Synthesis of 2-(4-substitutedphenyl) indole 
(1a-1c) was carried out by the procedure of 
Fischer Indole synthesis [18]. p-Substituted 
acetophenone phenylhydrazone was 
prepared by warming a mixture of 0.04175 
mole of acetophenone / p-methoxyaceto-
phenone / p-chloroacetophenone  and 
0.04175 mole of phenyl hydrazine with 60 
mLl of ethanol and few drops of glacial acetic 
acid. Filtered The reaction mixture was 
filtered, and the solid washed first with dilute 
HCl and then with 12 mL of cold rectified 
spirit. It was recrystallized with ethanol and 4 
g of the crude phenylhydrazone was placed 
in a beaker containing 25.71 g of 
polyphosphoric acid The mixture was heated 
over a boiling water bath and maintained at 
100  
0
C for 10 min. Cold water (65 ml) was 
added, stirred well, filtered and washed well 
with water.  
 




Synthesis of 2-(4-substitutedphenyl) indole-3-
carbaldehyde (2a-2c) was carried out by 
Vielsmayer Haack reaction. Anhydrous 
dimethylformamide  DMF (25 mL) was stirred 
at 0 
o
C for 15 min and 0.088 mole of 
phosphorous oxychloride was added to it 
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dropwise and stirred at 0 
o
C for 1 h. Indole 
(0.044 mole) was dissolved in anhydrous 
DMF and added dropwise to the above 
mixture < 10 
o
C. The mixture was warmed to 
35 - 40 
o
C and stirred for 1.5 h. Water (50 
mL) was added to the mixture, boiled for 2h, 
cooled and kept overnight. A solid mass, 
obtained after addition of water (30 mL), was 








(DMSO-d6):  δ 7.21-7.32 (m, 3H, Ar), 7.50 (d, 
J=8Hz,1H, Ar), 7.66 (d, J=8Hz,2H, Ar), 7.80 
(d, J=8Hz,2H, Ar),8.20 (d, J=8Hz, 1H, Ar ), 
9.96 (s, 1H, CHO), 12.48 (brs, 1H, NH). 2b  
IR (cm
-1
 , KBr): 3421, 3146, 3059, 2330, 
1720,1581,1445, 738; 
1
H NMR (DMSO-d6):  δ 
7.23-7.33 (m, 2H, Ar), 7.55 (d, J=8Hz,1H, Ar), 
7.71 (d, J=8Hz,2H, Ar), 7.82 (d, J=8Hz,2H, 
Ar),8.20 (d, J=8Hz, 1H, Ar ), 9.91 (s, 1H, 
CHO), 12.41 (brs, 1H, NH). 2c IR (cm
-1
 , 
KBr): 3360, 3062, 2329, 1734,1550, 
1249,741; 
1
H NMR (DMSO-d6):  δ 3.49 (s, 
3H, -OCH3) δ 7.21-7.42 (m, 3H, Ar), 7.69 (d, 
J=8Hz,2H, Ar), 7.88 (d, J=8Hz,2H, Ar),8.24 
(d, J=8Hz, 1H, Ar ), 9.98 (s, 1H, CHO), 12.42 
(brs, 1H, NH).  
 






phenone and piperidine (0.015 mole each) 
were mixed with 20 mL ethylene glycol. The 
solution was refluxed at 160 – 180 
o
C for 3 - 
4 h and cooled. The resulting solid was 
filtered and washed with 95 % ethanol. 3a IR 
(cm
-1
, KBr): 3235, 3146, 3010, 
1650,1575,1445, 745; 
1
H NMR (DMSO-d6):  δ 
6.98 (d, J=7Hz, 1H,=CH-Ar), 7.10-8.23 (m, 
14H, Ar), 8.08 (d, J=7Hz, 1H-COCH=),12.44 




 , KBr): 3233, 3120, 3010, 2289, 
1632,1550,1445, 738; 
1
H NMR (DMSO-d6):  δ 
6.82 (d, J=8 Hz, 1H =CH-Ar), 7.10-8.20 (m, 
13H, aromatic), 8.05 (d, J=12Hz, 1H-
COCH=),12.41 (brs, 1H, NH). 3c IR (cm
-1
 , 
KBr): 3360, 3126, 3015, 2250, 
1632,1552,1438, 781; 
1
H NMR (DMSO-d6):  δ 
2.37 (s, 1H, -CH3), 6.96 (d, J=12 Hz, 1H 
=CH-Ar), 7.19-8.23 (m, 13H, aromatic), 8.05 
(d, J=13 Hz, 1H-COCH=),12.09 (brs, 1H, 
NH). 3d IR (cm
-1
 , KBr): 3450, 3360, 3126, 
3015, 2250, 1632,1552,1438, 781; 
1
H NMR 
(DMSO-d6):  δ  7.06 (d, J=12 Hz, 1H =CH-
Ar), 7.16-7.98 (m, 13H, aromatic), 7.89 (d, 
J=13 Hz, 1H-COCH=), 9.15 (s, 1H, -
OH),12.39 (brs, 1H, NH). 3e IR (cm
-1
 , KBr): 
3410,3360, 3290, 3126, 3015, 2250, 
1632,1552,1438, 781; 
1
H NMR (DMSO-d6):  δ 
5.68 (s, 1H, NH2) 6.99 (d, J=12 Hz, 1H =CH-
Ar), 7.16-7.98 (m, 13H, aromatic), 8.02 (d, 
J=13 Hz, 1H-COCH=), 9.05 (s, 1H, -
OH),12.39 (brs, 1H, NH). 3f IR (cm
-1
 , KBr): 
3360, 3126, 3015, 2250, 1632,1552,1438, 
1243; 
1
H NMR (DMSO-d6):  δ 3.51 (s, 3H, -
OCH3), 5.68 (s, 1H, NH2) 6.79 (d, J=12 Hz, 
1H =CH-Ar), 7.16-7.98 (m, 13H, aromatic), 
8.06 (d, J=13 Hz,  1H-COCH=), 9.15 (s, 1H, -
OH),12.39 (brs, 1H, NH). 3g IR (cm
-1
 , KBr): 
3235, 3146, 3010, 2310, 1650,1575,1445, 
745; 
1
H NMR (DMSO-d6):  δ 6.88 (d, J=7Hz, 
1H,=CH-Ar), 7.10-8.23 (m, 14H, Ar), 8.18 (d, 
J=7Hz, 1H-COCH=),12.44 (brs, 1H, NH). 3h 
IR (cm
-1
 , KBr): 3233, 3120, 3010, 2289, 
1632,1550,1445, 763; 
1
H NMR (DMSO-d6):  δ 
6.92 (d, J=8 Hz, 1H =CH-Ar), 7.10-8.20 (m, 
13H, aromatic), 8.15 (d, J=12Hz, 1H-
COCH=),12.41 (brs, 1H, NH). 3i  IR (cm
-1
 , 
KBr): 3360, 3126, 3015, 2250, 
1632,1552,1438, 781; 
1
H NMR (DMSO-d6):  δ 
2.37 (s, 1H, -CH3), 6.95 (d, J=12 Hz, 1H 
=CH-Ar), 7.19-8.23 (m, 13H, aromatic), 7.99 
(d, J=13 Hz, 1H-COCH=),12.09 (brs, 1H, 
NH). 3j IR (cm
-1
 , KBr): 3450, 3360, 3126, 
3015, 2250, 1632,1552,1438, 781; 
1
H NMR 
(DMSO-d6):  δ  6.85 (d, J=12 Hz, 1H =CH-
Ar), 7.16-7.98 (m, 13H, aromatic), 8.03 (d, 
J=13 Hz, 1H-COCH=), 9.15 (s, 1H, -
OH),12.39 (brs, 1H, NH). 3k IR (cm
-1
 , KBr): 
3416, 3360, 3290, 3126, 3015, 2250, 
1632,1552,1438, 781; 
1
H NMR (DMSO-d6):  δ 
5.68 (s, 1H, NH2) 6.72 (d, J=12 Hz, 1H =CH-
Ar), 7.16-7.98 (m, 13H, aromatic), 8.12 (d, 
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J=13 Hz, 1H-COCH=), 9.05 (s, 1H, -
OH),12.39 (brs, 1H, NH). 3l  IR (cm
-1
 , KBr): 
3360, 3126, 3015, 2250, 1632,1552,1438, 
1243, 756; 
1
H NMR (DMSO-d6):  δ 3.51 (s, 
3H, -OCH3), 5.68 (s, 1H, NH2) 6.98 (d, J=12 
Hz, 1H =CH-Ar), 7.16-7.98 (m, 13H, 
aromatic), 8.06 (d, J=13 Hz, 1H-COCH=), 
9.15 (s, 1H, -OH),12.39 (brs, 1H, NH). 3m IR 
(cm
-1
 , KBr): 3360, 3126, 3015, 2250, 
1632,1552,1438, 1243, 756; 
1
H NMR 
(DMSO-d6):  δ 3.51 (s, 3H, -OCH3), 5.68 (s, 
1H, NH2) 6.97 (d, J=12 Hz, 1H =CH-Ar), 7.16-
7.96 (m, 13H, aromatic), 7.98 (d, J=13 Hz, 
1H-COCH=), 9.15 (s, 1H, -OH),12.39 (brs, 
1H, NH). 3n IR (cm
-1
 , KBr): 3360, 3126, 
3015, 2250, 1632,1552,1438, 1243, 756; 
1
H 
NMR (DMSO-d6):  δ 3.51 (s, 3H, -OCH3), 
5.68 (s, 1H, NH2) 6.84 (d, J=12 Hz, 1H =CH-
Ar), 7.16-7.98 (m, 13H, aromatic), 8.02 (d, 
J=13 Hz, 1H-COCH=), 9.15 (s, 1H, -
OH),12.39 (brs, 1H, NH). 3o IR (cm
-1
 , KBr): 
3360, 3126, 3015, 2250, 1632,1552,1438, 
1243, 756; 
1
H NMR (DMSO-d6):  δ 3.51 (s, 
3H, -OCH3), 5.68 (s, 1H, NH2) 6.89 (d, J=12 
Hz, 1H =CH-Ar), 7.16-7.98 (m, 13H, 
aromatic), 8.06 (d, J=13 Hz, 1H-COCH=), 
9.15 (s, 1H, -OH),12.39 (brs, 1H, NH). 3p IR 
(cm
-1
 , KBr): 3360, 3126, 3015, 2250, 
1632,1552,1438, 1243, 756; 
1
H NMR 
(DMSO-d6):  δ 3.51 (s, 3H, -OCH3), 5.68 (s, 
1H, NH2) 6.79 (d, J=12 Hz, 1H =CH-Ar), 7.16-
7.98 (m, 13H, aromatic), 8.15 (d, J=13 Hz, 
1H-COCH=), 9.15 (s, 1H, -OH),12.39 (brs, 
1H, NH).3q IR (cm
-1
 , KBr): 3360, 3126, 
3015, 2250, 1632,1552,1438, 1243, 756; 
1
H 
NMR (DMSO-d6):  δ 3.51 (s, 3H, -OCH3), 
5.68 (s, 1H, NH2) 6.92 (d, J=12 Hz, 1H =CH-
Ar), 7.16-7.98 (m, 13H, aromatic), 8.11 (d, 
J=13 Hz, 1H-COCH=), 9.15 (s, 1H, -
OH),12.39 (brs, 1H, NH).3r IR (cm
-1
 , KBr): 
3360, 3126, 3015, 2250, 1632,1552,1438, 
1243, 756; 
1
H NMR (DMSO-d6):  δ 3.51 (s, 
3H, -OCH3), 5.68 (s, 1H, NH2) 6.96 (d, J=12 
Hz, 1H =CH-Ar), 7.16-7.98 (m, 13H, 
aromatic), 8.09 (d, J=13 Hz, 1H-COCH=), 
9.15 (s, 1H, -OH),12.39 (brs, 1H, NH).  
 
General procedure for the synthesis of 4-
(4-substitutedphenyl)-6-(2-(4-
substitutedphenyl)-1H-indol-3-yl) 
pyrimidin-2-amine (4a-4r)  
 
Chalcones were cyclized with guanidine 
hydrochloride in the presence of sodium 
isopropoxide (synthesized in situ by adding 
sodium metal in isopropanol to give 
pyrimidines as follows: 
 
To a solution of 1.1 moles of guanidine 
hydrochloride in 50 mL of isopropanol, 1.1 
moles of sodium metal was added. The 
reaction mixture was refluxed for 2 h, 
chalcone (3a-3r, 1.0 equivalent) were added 
to it and then refluxed for 10 h. Solvent was 
removed from the reaction mixture under 
reduced pressure. Water (50 mL) was added 
and the aqueous phase extracted with 20 mL 
of ethyl acetate. The organic phase was dried 
over anhydrous Na2SO4, filtered and 
concentrated. The resulting product was 
recrystallized from ethanol, and their melting 
point, % yield and molecular formula are 




, KBr): 3410, 3355, 3175, 3126, 
3015, 1648,1590,1418, 1243, 756; 
1
H NMR 
(DMSO-d6):  δ  5.58 (s, 2H, NH2), 7.10-8.16 
(m, 15H, aromatic), 11.92 (brs, 1H, NH) ; 
Elemental (CHN) Analysis:  Anal. Calcd for 
C24H18 N4 C, 79.54; H, 5.01; N, 15.46 Found: 
C, 79.46; H, 5.02; N, 15.48. 4b IR (cm
-1
 , 
KBr): 3405, 3360,3218, 1640,1587,1425, 
1241, 746; 
1
H NMR (DMSO-d6):  δ 5.61 (s, 
2H, NH2), 7.20-8.22 (m, 14H, aromatic), 
11.87 (brs, 1H, NH); Elemental Analysis: 
Anal. Calcd for C24H17ClN4 C, , 72.63; H, 
4.32; Cl, 8.93; N, 14.12 Found: C, 72.62; H, 
4.36; N, 14.07. 4c IR (cm
-1
 , KBr): 3412, 
3361,3233, 3116, 1635,1620,1436, 1215, 
756; 
1
H NMR (DMSO-d6):  δ 2.39 (s, 1H, -
CH3), 5.42 (s, 2H, NH2), 7.16-8.21 (m, 14H, 
aromatic), 12.07 (brs, 1H, NH); Elemental 
Analysis: Anal. Calcd for C25H20N4 C, 79.76; 
H, 5.35; N, 14.88 Found: C, 79.70; H, 5.39; 
N, 14.92. 4d IR (cm
-1
 , KBr): 3456, 3350, 
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Table 1: Physical data for synthesized pyrimidinyl indole derivatives (4a-4r) 
 




C)  Yield (%) Rf 
values  
4a H H C24H18 N4 150-153 62.33 0.72 
4b H 4-Cl C24H17ClN4 167-171 55.23 0.66 
4c H 4-CH3 C25H20N4 164-169 72.56 0.56 
4d H 4-OH C24H18N4O 150-153 66.73 0.65 
4e H 4-NH2 C24H19N5 152-156 58.19 0.73 
4f H 4-OCH3 C25H20N4O 189-192 61.84 0.65 
4g Cl H C24H17ClN4 201-203 79.34 0.77 
4h Cl 4-Cl C24H16Cl2N4 179-181 58.12 0.69 
4i Cl 4-CH3 C25H19ClN4 205-208 62.18 0.70 
4j Cl 4-OH C24H17ClN4O 216-218 67.28 0.66 
4k Cl 4-NH2 C24H18ClN5 224-226 65.61 0.75 
4l Cl 4-OCH3 C25H19ClN4O 216-218 63.14 0.68 
4m OCH3 H C25H20N4O 197-199 59.42 0.67 
4n OCH3 4-Cl C25H19ClN4O 189-192 49.55 0.64 
4o OCH3 4-CH3 C26H22N4O 167-180 68.28 0.71 
4p OCH3 4-OH C25H20N4O2 147-150 65.58 0.73 
4q OCH3 4-NH2 C25H21N5O 171-173 68.13 0.74 
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Fig 1: Scheme for synthesis of the pyrimidines 
Reagent and conditions: (i) anhydrous DMF, POCl3; (ii) piperidine, ethylene glycol, reflux; (iii) guanidine 
HCl, sodium isopropoxide, reflux. 
Chavan et al  
Trop J Pharm Res, August 2011;10 (4): 468 
 
NMR (DMSO-d6):  δ 5.65 (s, 2H, NH2),  7.12-
8.10 (m, 14H, aromatic), 9.14 (s, 1H, -
OH),12.13 (brs, 1H, NH) ; Elemental 
Analysis: Anal. Calcd for C24H18N4O C, 76.17; 
H, 4.79; N, 14.81; O, 4.23 Found: C, 76.12; 
H, 4.69; N, 14.82. 4e IR (cm
-1
 , KBr): 3416, 
3356, 3126, 3011, 1632,1599,1448, 1241; 
1
H 
NMR (DMSO-d6):  δ 5.40 (s, 2H, NH2),  5.72 
(s, 1H, NH2), 7.13-8.22 (m, 14H, aromatic), 
12.18 (brs, 1H, NH) ; Elemental Analysis: 
Anal. Calcd for C24H19N5 C, 76.37; H, 5.07; N, 
18.55Found: C, 76.36; H, 5.06; N, 18.49. 4f 
IR (cm
-1
 , KBr): 3402, 3362, 3128, 
1638,1591,1438, 1242, 756; 
1
H NMR 
(DMSO-d6):  δ 3.58 (s, 3H, -OCH3),  5.64 (s, 
2H, NH2),  7.12-8.24 (m, 14H, aromatic), 
11.89 (brs, 1H, NH) ; Elemental Analysis: 
Anal. Calcd for C25H20N4O C, 76.51; H, 5.14; 
N, 14.28; O, 4.08 Found: C, 76.48; H, 5.18; 
N, 14.26. 4g IR (cm
-1
 , KBr): 3450,3368, 
3122, 3010, 1632,1598,1438, 1243, 763; 
1
H 
NMR (DMSO-d6):  δ 5.51(s, 2H, NH2),    7.10-
8.26 (m, 14H, aromatic), 12.26 (brs, 1H, NH) 
; Elemental Analysis: Anal. Calcd for 
C24H17ClN4C, 72.63; H, 4.32; Cl, 8.93; N, 
14.12 Found: C, 72.67; H, 4.34; N, 14.09. 4h 
IR (cm
-1
 , KBr): 3433, 3362, 3126, 3016, 
1652,1589,1436, 1243, 748; 
1
H NMR 
(DMSO-d6):  δ 5.59 (s, 2H, NH2),     7.08 -
8.31 (m, 13H, aromatic), 12.19 (brs, 1H, NH); 
Elemental Analysis: Anal. Calcd for 
C24H16Cl2N4 C, 66.83; H, 3.74; Cl, 16.44; N, 
12.99Found: C, 66.84; H, 3.69; N, 19.92. 4i 
IR (cm
-1
 , KBr): 3456, 3350, 3120, 3015, 
1630,1591,1438, 1241, 766; 
1
H NMR 
(DMSO-d6):  δ 2.40 (s, 3H, CH3), 5.64 (s, 2H, 
NH2),      7.16-8.09 (m, 13H, aromatic), 12.17 
(brs, 1H, NH) ; Elemental Analysis: Anal. 
Calcd for C25H19ClN4 C73.08; H, 4.66; Cl, 
8.63; N, 13.64 Found: C, 73.04; H, 4.69; N, 
13.61. 4j IR (cm
-1
 , KBr): 3460, 3365, 3123, 
1636,1592,1438, 1241, 756; 
1
H NMR 
(DMSO-d6):  δ 5.46  (s, 2H, NH2),      7.19-
8.03 (m, 13H, aromatic), 9.18 (s, 1H, -
OH),12.27 (brs, 1H, NH) ; Elemental 
Analysis: Anal. Calcd for C24H17ClN4O C, 
69.82; H, 4.15; Cl, 8.59; N, 13.57; O, 3.88 
Found:  C, 69.80; H, 4.12; N, 13.54. 4k IR 
(cm
-1
 , KBr): 3418, 3362, 3126, 3016, 
1632,1588,1436, 1243, 748; 
1
H NMR 
(DMSO-d6):  δ 5.62 (s, 2H, NH2) 5.71 (s, 2H, 
NH2), 7.14-8.01 (m, 13H, aromatic), 12.21 
(brs, 1H, NH) ; Elemental Analysis: Anal. 
Calcd for C24H18ClN5 C, 69.98; H, 4.40; Cl, 
8.61; N, 17.00 Found : C, 69.93; H, 4.43; N, 
17.03. 4l IR (cm
-1
 , KBr): 3422, 3362, 3123, 
1638,1590,1438, 1243, 756; 
1
H NMR 
(DMSO-d6):  δ, 3.46 (s, 3H, -OCH3),  5.44 (s, 
2H, NH2), 7.14-8.02 (m, 13H, aromatic), 
12.17 (brs, 1H, NH) ; Elemental Analysis: 
Anal. Calcd for C25H19ClN4O C, 70.34; H, 
4.49; Cl, 8.30; N, 13.12; O, 3.75Found C, 
70.32; H, 4.43; N, 13.10. 4m IR (cm
-1
 , KBr): 
3512, 3356, 3126, 3012, 1630,1589,1448, 
1241, 746; 
1
H NMR (DMSO-d6):  δ 3.47 (s, 
3H, -OCH3), 5.54 (s, 2H, NH2), 7.10-8.01 (m, 
14H, aromatic),12.31 (brs, 1H, NH) ; 
Elemental Analysis: Anal. Calcd for 
C25H20N4O C, 76.51; H, 5.14; N, 14.28; O, 
4.08 Found C, 76.49; H, 5.12; N, 14.21. 4n IR 
(cm
-1
 , KBr): 3456, 3350, 3120, 3015, 
1630,1591,1438, 1241, 766; 
1
H NMR 
(DMSO-d6):  δ  3.48 (s, 3H, -OCH3), , 5.64 (s, 
2H, NH2), 7.29-8.11 (m, 13H, aromatic), 
12.20 (brs, 1H, NH) ; Elemental Analysis: 
Anal. Calcd for C25H19ClN4O C, 70.34; H, 
4.49; Cl, 8.30; N, 13.12; O, 3.75 Found:  C, 
70.31; H, 4.46; N, 13.10. 4o IR (cm
-1
 , KBr): 
3436, 3360, 3126, 3015, 1632,1599,1432, 
1243, 756; 
1
H NMR (DMSO-d6):  δ 2.37 (s, 
3H, CH3), 3.49 (s, 3H, -OCH3), 5.61 (s, 2H, 
NH2), 7.20-8.04 (m, 13H, aromatic), 12.18 
(brs, 1H, NH) ; Elemental Analysis: Anal. 
Calcd for C26H22N4O C, 76.83; H, 5.46; N, 
13.78; O, 3.94 Found:  C, 76.79; H, 5.47; N, 
13.74. 4p IR (cm
-1
 , KBr): 3458,3432, 3351, 
3123, 1632,1596,1438, 1247, 756; 
1
H NMR 
(DMSO-d6):  δ  3.46 (s, 3H, -OCH3), 5.55 (s, 
2H, NH2),  7.21-8.12 (m, 13H, aromatic), 9.16 
(s, 1H, -OH),12.28 (brs, 1H, NH) ; Elemental 
Analysis: Anal. Calcd for C25H20N4O2 C, 
73.51; H, 4.94; N, 13.72; O, 7.83 Found: C, 
73.48; H, 4.88; N, 13.74. 4q IR (cm
-1
 , KBr): 
3410, 3349, 3116, 3019, 1630,1579,1438, 
1243, 747; 
1
H NMR (DMSO-d6):  δ 3.42 (s, 
3H, -OCH3), 5.58 (s, 2H, NH2),   5.70 (s, 2H, 
NH2), 7.01-7.98 (m, 13H, aromatic), 12.24 
(brs, 1H, NH) ; Elemental Analysis: Anal. 
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Calcd for C25H21N5O C, 73.69; H, 5.19; N, 
17.19; O, 3.93 Found: C, 73.63; H, 5.18; N, 
17.16. 4r IR (cm
-1
 , KBr): 3435, 3368, 3128, 
3017, 1632,1595,1436, 1243, 746; 
1
H NMR 
(DMSO-d6):  δ 3.45 (s, 3H, -OCH3), 5.56 (s, 
2H, NH2),   7.13-8.11 (m, 13H, aromatic), 
12.21 (brs, 1H, NH) ; Elemental Analysis: 
Anal. Calcd for C26H22N4O2 C, 73.92; H, 5.25; 
N, 13.26; O, 7.57 Found: C, 73.90; H, 5.22; 
N, 13.25. 
 
Characterization of synthesized 
compounds  
 
Melting point was determined in an open 
capillary on Veego electronic apparatus 
(model:-VMP-D) and are uncorrected. 
Infrared  IR spectra of the synthesized 
compounds were recorded on Shimadzu 
8400-S FT-IR spectrophotometer using 
potassium bromide while 
1
H NMR spectra 
were recorded in DMSO-d6 using NMR 
Varian-Mercury 300 MHz spectrometer and 
chemical shifts are reported as parts per 
million (ppm) using tetramethylsilane (TMS) 
as an internal standard. Carbon, hydrogen 
and nitrogen (C, H and N, respective) 
analyses were carried out on a CE 
Instruments EA 1110 analyzer. To monitor 
the reactions and establish the identity and 
purity of reactants and products, thin layer 
chromatography (TLC) was performed on 
microscopic glass slides (2 x 7.5 cm) coated 
with silica gel-G (Merck), using toluene-
methanol and chloroform-methanol as the 
solvent systems; the spots were visualized by 
exposure to iodine vapors, dilute sulfuric acid 




Wistar rats (150 - 200 g) and albino mice (25 
- 30 g) of either sex were selected for the 
experiments. The animals were acclimatized 
for a period of two weeks in our laboratory 
environment prior to the study. They were 
housed in polypropylene cages, maintained 
under standard laboratory conditions, andfed 
with standard diet and water ad libitum. The 
principles of National Institutes of Health NIH 
Guide for Care and Use of Laboratory 
Animals (pub. No. 85-23, revised 2002) and 
the instructions given by the institutional 
Animal Ethical Committee (which had 
approved the animal studies vide letter no. 
COPS/174/2009-10) were followed 
throughout the experiment.  
 
Assessment of anti-inflammatory activity  
 
Anti-inflammatory activity was evaluated 
using carrageenan-induced rat paw edema 
model [19]. Wistar rats (150 - 200 g) were 
divided into groups of six animals each. 
Group 1 served as control group and 
received saline, group 2 received 
indomethacin (10 mg/kg) and other groups 
received test drugs in a dose of 20 mg/kg. 
The drugs were prepared as homogenous 
suspensions in saline (0.9 % NaCl) and 
administered orally to animals. One hour after 
drug administration, each rat received a sun 
planter injection of 0.1 ml of 1 % carrageenan 
solution in its left paw. Measurement of the 
hind paw volume was carried out using a 
plethysmometer prior to treatment (Vo), and 2 
and 3 h (Vt) after drug administration. 
Inhibition of swelling by the drugs was 
calculated using Eq 1. 
 
Inhibition (%) = {[(Vt- Vo) control-(Vt-Vo) 
treated]/ (Vt- Vo) control} x100 …….…… (1) 
 
where Vt and Vo relates to the mean volume 
of the hind paw of the rats (n=6) before and 
after anti-inflammatory agent treatment, 
respectively. The results are shown in Table 
2. 
 
Analgesic activity  
 
All the compounds were tested for analgesic 
activity, using the acetic acid induced writhing 
method [20] in albino mice (25 - 30 g) of 
either sex. A 0.6 % v/v solution of acetic acid 
was used as writhing-inducing agent. The 
test compounds and indomethacin were 
administered orally 1 h prior to acetic acid 
injection. The mice were divided into groups 
of six animals each.  Group 1 served as 
control group and received saline, group 2 
received indomethacin (10 mg/kg) while the 
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other groups received test drugs in a dose of 
20 mg/kg. The drugs were prepared as 
homogenous suspensions in saline (0.9 % 
NaCl) and administered orally to the animals. 
The writhing-inducing agent was 
administered intraperitonially. The number of 
writhings within a period of 20 min after drug 
administration was counted for each of the 
animal groups. Protection was calculated 
using Eq 2. 
 
 
Table 2: Anti-inflammatory effects of the 
synthesized pyrimidinyl indoles derivatives in 
carrageenan-induced rat paw edema 
 
Inhibition (%, mean± SEM) Compound 
2 h 3 h 
4a 55.9 ± 2.7 67.7 ± 3.3** 
4b 44.0 ± 2.0 54.7 ± 3.2  
4c 60.3 ± 2.6 71.9 ± 2.8** 
4d 61.3 ± 1.7 72.5 ± 1.2** 
4e 62.4± 2.1 69.7 ± 3.2** 
4f 59.4 ± 2.6 68.9 ± 1.1 
4g 49.3 ± 1.6 55.8 ± 1.4 
4h 67.2 ± 2.4 77.7 ± 2.9** 
4i 50.6 ± 1.6  62.1 ± 2.4 
4j 79.3 ± 0.6 87.3 ± 2.1** 
4k 76.7 ± 1.7 88.2 ± 1.5** 
4l 57.8 ± 2.2 65.3 ± 1.3**  
4m 49.4 ± 3.3 54.8 ± 4.1 
4n 59.6 ± 1.6 71.5 ± 2.2**  
4o 49.9 ± 2.3 61.4 ±1.9 
4p 63.8 ± 1.0  75.0 ± 3.1** 
4q 69.2 ± 1.6 78.9 ± 2.1** 
4r 54.2 ± 2.2 68.3 ± 1.8** 
Control -- -- 
Indomethacin 84.1 ± 1.04 92.7 ± 1.79 
Dose of compound = 20 mg/kg; indomethacin 




Protection (%) = 100(100 – W1)./ W1  ……….. (2) 
 
where W1 is the number of writhins of test 
group and W2 is the number of writhings in 
the control group. The results are expressed 
as % decrease in writhing with respect to 
control and presented in Table 3. 
 
Evaluation of acute ulcerogenesis  
 
The studies were carried out using healthy 
Wistar rats (150 - 200 g) at thrice the dose 
(60 mg/kg) given in the anti-inflammatory 
studies. [21]. The animals were divided into 
different groups of six animals each. Group 1 
served as control and received vehicle (1% 
aqueous methylcellulose dispersion) only, 
group 2 received the standard drug 
(indomethacin, 60 mg/kg) while the other 
groups were administered test compounds in 
doses molecularly equivalent to 60 mg/kg of 
indomethacin. The animals were fasted 6 h 
prior to receiving a single dose of either 
vehicle, standard or test compound. 
Following drug treatment, the rats were fed 
normal diet and then sacrificed after 
chloroform anaesthesia 14 h later.. The 
gastric mucosa of the rats was examined with 
the aid of a magnifier. For each stomach, the 
severity of mucosal damage was assessed 
according to the following scoring system: 0 = 
≤ 5 punctiform lesions; 1 = > 5 punctiform 
lesions; 2 = one to five small ulcers; 3 = more 
than five small ulcers of one large ulcer; 4 = 
 
Table 3: Analgesic effect of synthesized 
pyrimidinyl indole derivatives in acetic acid-
induced writhing in rats 
 
Compound No. of 
writhings 
(mean±SEM) 
Decrease in  
writhing (%) 
4a 15.3 ± 0.60 55.9 
4b 17.8± 0.47 48.8 
4c 13.0 ± 0.76 62.6** 
4d 10.0 ± 0.85 71.3** 
4e 11.5± 0.61 66.8** 
4f 29.3 ± 0.57 44.4 
4g 14.7 ± 0.66 57.8** 
4h 6.2 ± 0.47 82.2** 
4i 14.7 ± 0.84  57.7** 
4j 7.5 ± 0.30 78.4** 
4k 8.2 ± 0.47 76.4** 
4l 13.8± 0.49 60.3** 
4m 12.0 ± 0.57 65.4** 
4n 15.5 ± 0.42 55.4 
4o 12.7 ± 0.74 63.5** 
4p 11.8 ± 0.87 66.0** 
4q 7.2 ± 0.85 79.3** 
4r 19.3 ± 0.61 44.5 
Control 34.8 ± 0.87 - 
Indomethacin 6.0 ± 0.42 82.7 
Dose of compound = 20 mg/kg; indomethacin dose = 10 
mg/kg; ** values are significant at p < 0.01 
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more than one large ulcer. The mean score 
of each treated group minus the mean score 
of the control group was taken as the 
‘severity index’ of gastric damage (p < 0.001). 
The data are shown in Table 4.   
 
Table 4: Ulcerogenic activity (severity index) 
of synthesized compounds on the gastric 
mucosa of rats  
 
Compound Severity index 
4a 1.49 ± 0.22 
4b 1.52 ± 0.33 
4c 1.83 ± 0.30** 
4d 0.94 ± 0.21** 
4e 1.13 ± 0.24** 
4f 1.44 ± 0.27** 
4g 0.88 ± 0.33** 
4h 0.89 ± 0.19** 
4i 1.65 ± 0.34** 
4j 0.89 ± 0.30** 
4k 1.12 ± 0.47** 
4l 1.93± 0.40 
4m 1.21 ± 0.27** 
4n 1.52 ± 0.42** 
4o 1.96 ± 0.34 
4p 0.98 ± 0.47** 
4q 1.01 ± 0.25** 
4r 1.56 ± 0.49** 
Control 0.00 
Indomethacin 2.24 ± 0.30** 
 
Compound/indomethacin dose =60 mg/kg;  




The data were analysed by one-way ANOVA 
followed by Dunnet’s t-test using 
computerized GraphPad Prism software, 
version 5. All the results are expressed as 





The inhibition of swelling in carrageenan-
induced edema in rat paw brought about by 
oral administration of the drug is shown in 
Table 2.  
 
All the synthesized compounds tested for 
anti-inflammatory activity showed inhibition of 
edema ranging from 54.8 to 88.2 %, 
especially compounds 4d, e, j, k, q and p 
which demonstrated very good anti-
inflammatory activity. In particular, 4-(2-
amino-6-(2-(4-chlorophenyl)-1H-indol-3-
yl)pyrimidin-4-yl)phenol (4j, 87.4 %) and 4-(4-
aminophenyl)-6-(2-(4-chlorophenyl)-1H-indol-
3-yl)pyrimidin-2-amine (4k, 88.2 %) were 
equipotent with indomethacin (92.7%) in 






Compounds (4a - 4r) were tested for 
analgesic activity at the same dose as for 
antiinflammatory activity. Analgesic activity, 
measured by % protection against writhing in 
mice afforded by the drugs, is shown in Table 
3. The compounds tested showed analgesic 
activity in the range of 44.5 to 82.3 %. 
Compounds 4h and 4q were especially 
potent showing 82.3 and 79.4 % protection, 
respectively, against acetic acid-induced 
writhing which compares well with 82.8 % for 
indomethacin. The analgesic effects of the 
compounds were in a similar way to their 




Ulcerogenic effect was studied at 60 mg/kg in 
rats (thrice the dose used in the earlier tests) 
and the data are shown in Table 4. The 
ulcerogenic effect, measured by severity 
index, of compounds 4a - 4r (0.88 to 1.96) 
was appreciably less than that of 
indomethacin (2.16). Ulcerogenic effect was 
especially low for compounds 4d, 4g, 4h 4j 
and 4p with severity index of 0.94, 0.88, 0.89, 




The purpose of the present study was to 
examine whether molecular modification of 
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indole and pyrimidine would result in 
molecules with good analgesic/anti-
inflammatory actions and less ulcerogenic 
effects. A series of compounds was 
synthesized and evaluated for biological 
activities. The data obtained indicate that 
compounds having indole nucleus with 
substituted phenyl ring at 2-position and 
substituted pyrimidine ring at 3-position are 
not only good analgesic and anti-
inflammatory agents but exhibited less 
ulcerogenic effect. Pyrimidines having 
substituted phenyl ring at 6
th
 position were in 
general more active than unsubstituted ones, 
indicating that the presence of functional 
group may be helpful in orienting the 
molecule in active site. Pyrimidines having 
hydroxyl and amino group substituted at para 
position of phenyl ring at position-6 were 
found to be more active than others, 
indicating that the presence of groups 
forming hydrogen bonds may aid more 
efficient binding with the receptors. The 
presence of an electronegative group at para 
position of 2-phenyl ring on indole nucleus 
seems to be important for good 
antiinflammatory action.  
These findings suggest that the newly 
synthesized compounds will produce less 
gastric irritation and may be considered as 
safer drugs for treating inflammatory 
conditions. Compounds with 4-chlorophenyl 
and 4-aminophenyl rings at 6
th
 position of the 
pyrimidine ring showed higher analgesic 




Various derivatives of 3-(2-aminopyrimidin-4-
yl) indoles were successfully synthesized and 
screened for their analgesic, anti-
inflammatory and ulcerogenic activities. The 
tested compounds showed comparable 
analgesic and anti-inflammatory activities 
with indomethacin but were less irritant to the 
gastric mucosa. The results obtained support 
our hypothesis that chemical hybridization of 
indole nucleus and pyrimidine ring at the 
appropriate position affords compounds with 
good analgesic and antiinflammatory 
activities, and less gastric irritation. Further 
studies are planned to include in vitro COX 2 
assay as well as elucidation of quantitative 
structure-activity relationship, leading to the 
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